The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats
Abstract
Silymarin (SIL), a standardized plant extract containing about 60% polyphenole silibinin, is used as a hepatoprotective agent. Its antifibrotic potential in chronic liver diseases has not been explored. Therefore, we applied SIL to adult Wistar rats that were subjected to complete bile duct occlusion (BDO) by injection of sodium amidotrizoate (Ethibloc). This treatment induces progressive portal fibrosis without significant inflammation. Rats with sham-operation that received SIL at 50 mg/kg/d (n = 10) and rats with BDO alone (n = 20) served as controls, whereas groups of 20 animals were fed SIL at a dose of 25 and 50 mg/kg/d during weeks 1 through 6 or doses of 50 mg/kg/d during weeks 4 through 6 of BDO. Animals were sacrificed after 6 weeks for determination of blood chemistries, total and relative liver collagen (as hydroxyproline [HYP]), and the serum aminoterminal propeptide of procollagen type III (PIIINP). BDO in untreated rats caused an almost ninefold increase in total liver collagen (16.1 ± 3.1 vs. 1.8 ± 0.4 mg HYP, P < .001). SIL at 50 mg/kg/d reduced total HYP by 30% to 35%, either when given from week 1 through 6 or from week 4 through 6 after BDO (10.6 ± 2.7 and 10.2 ± 3.9 mg HYP, both P < .01 vs. BDO alone), whereas 25 mg/kg/d were ineffective. Because SIL at 50 mg/kg/d also reduced the collagen content per gram of liver tissue, it acted as a true antifibrotic agent. The single value of PIIINP at killing paralleled the antifibrotic activity of SIL with 11.6 ± 3.8 and 9.9 ± 3.7 vs. 15.3 ± 5.2 microg/L in both high-dose groups (P < .05 and P < .01, respectively, vs. rats with BDO alone). Except for a decreased alkaline phosphatase and a lower histological fibrosis score in the groups that received SIL, clinical-chemical parameters were not different among all groups with BDO. We therefore conclude that 1) BDO with Ethibloc is a suitable model to test for pure antifibrotic drugs because it induces progressive rat secondary biliary fibrosis without major inflammation; 2) oral SIL can ameliorate hepatic collagen accumulation even in advanced (biliary) fibrosis; and 3) PIIINP appears to be a suitable serum marker to monitor the inhibition of hepatic fibrogenesis in this model of biliary fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies
Flier, J. S., Underhill, L. H., & Friedman, S. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282508 · Cited by 1,432
A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues
Jamall, I. S., Finelli, V. N., & Que Hee, S. S. (1981) · Analytical Biochemistry · doi:10.1016/0003-2697(81)90261-x · Cited by 518
Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver
Ferenci, P., Dragosics, B., Dittrich, H., Frank, H., Benda, L., Lochs, H., Meryn, S., Base, W., & Schneider, B. (1989) · Journal of Hepatology · doi:10.1016/0168-8278(89)90083-4 · Cited by 496
Silymarin protects against paracetamol‐induced lipid peroxidation and liver damage
Muriel, P., Garciapiña, T., Perez‐Alvarez, V., & Mourelle, M. (1992) · Journal of Applied Toxicology · doi:10.1002/jat.2550120613 · Cited by 301
Dehmlow, C., Erhard, J., & de Groot, H. (1996) · Hepatology · doi:10.1002/hep.510230415 · Cited by 290
Scavenging of reactive oxygen species by silibinin dihemisuccinate
Mira, L., Silva, M., & Manso, C. F. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90053-1 · Cited by 192
PREVENTION OF CCL4‐INDUCED LIVER CIRRHOSIS BY SILYMARIN
MOURELLE, M., MURIEL, P., FAVARI, L., & FRANCO, T. (1989) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1989.tb00449.x · Cited by 159
BOSISIO, E. (1992) · Pharmacological Research · doi:10.1016/1043-6618(92)91383-r · Cited by 158
Suppression of experimental hepatic fibrosis by administration of vitamin A.
Senoo, H., & Wake, K. (1985) · PubMed · Cited by 158
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“The consideration as a hepatoprotective agent is due to experimental data indicating potential prevention of hepatic injury by toxins and deceleration of fibrosis progression by the main ingredient, silibinin [359,360].”
BackgroundOxidative stress-related molecules and liver fibrosis
Parola, M., & Robino, G. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00142-8 · Cited by 783
The Use of Silymarin in the Treatment of Liver Diseases
Saller, R., Meier, R., & Brignoli, R. (2001) · Drugs · doi:10.2165/00003495-200161140-00003 · Cited by 718
Milk thistle in liver diseases: past, present, future
Abenavoli, L., Capasso, R., Milic, N., & Capasso, F. (2010) · Phytotherapy Research · doi:10.1002/ptr.3207 · Cited by 599
Cutaneous photodamage, oxidative stress, and topical antioxidant protection
Pinnell, S. R. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.16 · Cited by 544
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
Federico, A., Dallio, M., & Loguercio, C. (2017) · Molecules · doi:10.3390/molecules22020191 · Cited by 492
Silymarin: A Review of its Clinical Properties in the Management of Hepatic Disorders
Wellington, K., & Jarvis, B. (2001) · BioDrugs · doi:10.2165/00063030-200115070-00005 · Cited by 479
Hepatoprotective effect of silymarin
Vargas-Mendoza, N. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i3.144 · Cited by 447
Treatment of Amatoxin Poisoning: 20-Year Retrospective Analysis
Enjalbert, F., Rapior, S., Nouguier-Soulé, J., Guillon, S., Amouroux, N., & Cabot, C. (2002) · Journal of Toxicology: Clinical Toxicology · doi:10.1081/clt-120014646 · Cited by 427
Redox mechanisms in hepatic chronic wound healing and fibrogenesis
Novo, E., & Parola, M. (2008) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-1-5 · Cited by 406
Fraschini, F., Demartini, G., & Esposti, D. (2002) · Clinical Drug Investigation · doi:10.2165/00044011-200222010-00007 · Cited by 380
Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats
Dooley, S., Hamzavi, J., Breitkopf, K., Wiercinska, E., Said, H. M., Lorenzen, J., Ten Dijke, P., & Gressner, A. M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00666-8 · Cited by 369
Herbal medicine in the treatment of liver diseases
Stickel, F., & Schuppan, D. (2007) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.11.004 · Cited by 364
Self-citationDesmoulière, A., Darby, I. A., & Gabbiani, G. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000101911.53973.90 · Cited by 363
Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy
Li, D., & Friedman, S. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.01928.x · Cited by 343
Omenetti, A., Porrello, A., Jung, Y., Yang, L., Popov, Y., Choi, S. S., Witek, R. P., Alpini, G., Venter, J., Vandongen, H. M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35875 · Cited by 341
Self-citationHepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316
Dietary Antioxidant Compounds and Liver Health
Vitaglione, P., Morisco, F., Caporaso, N., & Fogliano, V. (2004) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408690490911701 · Cited by 305
Angiotensin-Converting Enzyme Inhibition Attenuates the Progression of Rat Hepatic Fibrosis
Jonsson, J. R., Clouston, A. D., Ando, Y., Kelemen, L. I., Horn, M. J., Adamson, M. D., Purdie, D. M., & Powell, E. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25480 · Cited by 295
Herbal products for liver diseases: A therapeutic challenge for the new millennium
Schuppan, D., Jia, J.-D., Brinkhaus, B., & Hahn, E. G. (1999) · Hepatology · doi:10.1002/hep.510300437 · Cited by 279
Self-citationHepatic stellate cells: a target for the treatment of liver fibrosis
Wu, J., & Zern, M. A. (2000) · Journal of Gastroenterology · doi:10.1007/s005350070045 · Cited by 273
Complementary and alternative medicine in chronic liver disease
Seeff, L. B., Lindsay, K. L., Bacon, B. R., Kresina, T. F., & Hoofnagle, J. H. (2001) · Hepatology · doi:10.1053/jhep.2001.27445 · Cited by 271
Impact of oestrogens on the progression of liver disease
Shimizu, I. (2003) · Liver International · doi:10.1034/j.1600-0676.2003.00811.x · Cited by 207
Metadata
- Authors
- Boigk, G., Stroedter, L., Herbst, H., Waldschmidt, J., Riecken, E. O., & Schuppan, D.
- Venue
- Hepatology
- Published
- 1997-09
- Volume
- 26
- Issue
- 3
- Pages
- 643-649
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1965452357
- Cited by
- 293
- References
- 21
- FWCI
- 9.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.